Neuraxpharm provides business update on a transformational year
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today provides a business update for the last twelve months.
Following the rebranding of the company in October 2018 to Neuraxpharm from NuPharm Group, Neuraxpharm has made great strides to build a sustainable business in the past year, delivering on its strategy of becoming a CNS specialist in Europe.
With an expanded presence in nine countries and over 750 employees, Neuraxpharm is on track to achieve gross sales of EUR 400m by the end of 2019. CNS products account for 85% of sales, with direct sales in Europe representing 85% of total sales for the Company. In Spain and Germany, Neuraxpharm ranks as one of the fastest growing of the 50 biggest pharmaceuticals companies in these countries.